Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause T1D: Paving the Path to Prevention Adult Immunization Center Dermatology Hot Topics

Medical Economics Editorial Staff

home / authors / medical-economics-editorial-staff

Articles

Medicare Part D Phase 2 Price Negotiations Target Semaglutide (Wegovy) Plus 14 More ©Corona Borealis/stock.adobe.com

Medicare Part D Phase 2 Price Negotiations Target Semaglutide (Wegovy) Plus 14 More

Medical Economics Editorial Staff

January 17th 2025

Price negotiations, effective in 2027, cover drugs for diabetes, cancer, COPD, and more, aiming for substantial Medicare savings.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.